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Background: G protein-coupled receptors (GPCRs) are the targets of a large number of drugs currently in
therapeutic use. Likewise, the glutamate ionotropic N-methyl-D-aspartate receptor (NMDAR) has been implicated in
certain neurological disorders, such as neurodegeration, neuropathic pain and mood disorders, as well as psychosis
and schizophrenia. Thus, there is now an important need to characterize the interactions between GPCRs and
NMDARs. Indeed, these interactions can produce distinct effects, and whereas the activation of Mu-opioid receptor
(MOR) increases the calcium fluxes associated to NMDARs, that of type 1 cannabinoid receptor (CNR1) antagonizes
their permeation. Notably, a series of proteins interact with these receptors affecting their responses and
interactions, and then emerge as novel therapeutic targets for the aforementioned pathologies.
Results: We found that in the presence of GPCRs, the HINT1 protein influences the activity of NMDARs, whereby
NMDAR activation was enhanced in CNR1+/+/HINT1−/− cortical neurons and the cannabinoid agonist WIN55,212-2
provided these cells with no protection against a NMDA insult. NMDAR activity was normalized in these cells by the
lentiviral expression of HINT1, which also restored the neuroprotection mediated by cannabinoids. NMDAR activity
was also enhanced in CNR1−/−/HINT1+/+ neurons, although this activity was dampened by the expression of GPCRs
like the MOR, CNR1 or serotonin 1A (5HT1AR).
Conclusions: The HINT1 protein plays an essential role in the GPCR-NMDAR connection. In the absence of receptor
activation, GPCRs collaborate with HINT1 proteins to negatively control NMDAR activity. When activated, most
GPCRs release the control of HINT1 and NMDAR responsiveness is enhanced. However, cannabinoids that act
through CNR1 maintain the negative control of HINT1 on NMDAR function and their protection against glutamate
excitotoxic insult persists.
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NeuroprotectionBackground
The glutamatergic N-methyl-D-aspartate (NMDA) recep-
tor has a significant influence on the efficacy of neuro-
transmission and synaptic plasticity, and on processes
such as learning and memory. The activation of this
ionotropic receptor results in the permeation of Ca2+ ions,
and it is positively regulated by certain G protein-coupled
receptors (GPCRs) through the activity of PKC and Src
[1,2]. Whilst, the Mu-opioid receptor (MOR) interacts
with the NMDAR [3] positively regulating NMDAR* Correspondence: jgarzon@cajal.csic.es
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distribution, and reproduction in any mediumcalcium fluxes [4], the cannabinoid 1 receptor (CNR1)
dampens the activity of this glutamate ionotropic receptor
[5]. Notably, the regulation of MORs and of CNR1s on
NMDARs activity requires the histidine triad nucleotide-
binding protein 1 (HINT1), and in its absence these
interactions are weakened to the extent that morphine no
longer stimulates NMDAR activity and WIN55,212-2 fails
to inhibit it [5-7].
The activation of CNR1s in the presynapse reduces the
release of glutamate into the cleft and contributes to
NMDAR hypofunction [8]. Nevertheless, CNR1s in the
postsynapse also negatively regulate NMDAR function byd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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nabinoids prevent the endogenous increase of calcium
through mechanisms related to the direct inhibition of
NMDAR calcium influx [9,10], as also suggested using
whole-cell patch clamp recording techniques [11]. This
mechanism would account for cannabinoid control of
exogenous activators of NMDAR function. Thus, besides
interacting with distant signaling pathways, cannabinoids
can also directly affect the open probability of the NMDAR
calcium channel. Immunocytochemical and ultrastructural
studies demonstrated the presence of CNR1s in the post-
synapse at both the spinal [12-14] and supraspinal level
[15,16], where they co-localize with NMDARs and PSD95
proteins [5,17]. Indeed, co-immunoprecipitation assays
performed ex vivo on mouse cerebral cortical synapto-
somes and in vitro studies with recombinant proteins
revealed the association between CNR1s and NMDARs
[5,18]. In the context of CNR1-NMDAR association, can-
nabinoids disassemble and inactivate CNR1-associated
NMDARs through the co-internalization of NR1 subunits
[5], and probably of surface NMDAR NR2 subunits as
well [19].
HINT1 is a 126 amino acid protein of approximately
14 kDa that belongs to the histidine triad (HIT) family,
all members of which contain the HisXHisXHis se-
quence (where X is any hydrophobic amino acid).
HINT1 binds zinc and purine nucleotides, and while it
exists as a zinc-independent homodimer, zinc ions medi-
ate the interaction between HINT1 and third party pro-
teins [6,20,21]. This protein was initially referred to as a
protein kinase C-interacting protein (PKCi) as it binds
to and inhibits PKC function in a zinc-dependent man-
ner [22]. However, this activity has since been relegated
in favor of its enzymatic activity [23]. Notwithstanding,
HINT1 appears to be implicated in a wide variety of
physiological processes, some of these functions are in-
dependent of HINT1 enzymatic activity [24], such as
DNA damage response pathways and tumor suppression
pathways [25], repression of β-catenin signaling and
transcriptional regulation [26], and regulation of cell en-
dogenous calcium signaling [27]. Furthermore, there is
evidence that at the plasma membrane HINT1 regulates
GPCR function via PKC [7,28-31], and that it regulates
the interaction of NMDARs with GPCRs like the MOR
and CNR1 [5,6]. At the cell membrane, HINT1 exists as
a homodimer and it behaves as a scaffold protein regu-
lated by Redox processes that bring together different
signaling pathways under the regulation of GPCRs
[32,33]. In this way it is possible to reconcile the enzym-
atic activity of the HINT1 protein with its role as a
switch in conveying information mediated by GPCR to
different signaling pathways, e.g., glutamate NMDAR-
mediated synaptic plasticity, β-catenin regulation, cal-
cium signaling and DNA repair.HINT1 associates directly with the cytosolic regions of
NMDAR NR1 subunits and with those of certain GPCRs,
recruiting a series of signaling proteins to the receptor
environment [5,30-32]. Indeed, the cytosolic C terminal
sequence of the MOR, and also that of CNR1, bind the
cytosolic C1 segment of the NMDAR NR1 subunit, and
HINT1 stabilizes this association [5,6]. Morphine chal-
lenge promotes the assembly and dis-assembly a series of
signaling proteins at the MOR-HINT1 complex in order
to enhance the activity of the NMDAR [30,31], which in
turn negatively controls the effects of opioids [34,35]. The
activation of the CNR1 has the opposite effect and it
diminishes NMDAR activity. The negative regulation
of NMDARs is particularly relevant because overactivation
of NMDARs produces a series of perturbations that are
associated with neurodegenerative diseases [36], mood
disorders such as schizophrenia and depression [37,38],
and neuropathic pain [39,40]. Indeed, cannabinoids are
highly efficient in reducing calcium permeation mediated
by NMDARs and in protecting neurons from the potential
risks of excessive NMDAR activity [41,42]. Cannabinoid
receptors are distributed throughout the central nervous
system [43] and the CNR1 is present at high densities in
presynaptic terminals [44], as well as in postsynaptic struc-
tures of spinal and supraspinal glutamatergic synapses
[12,14,15]. As the HINT1 protein associates with the cyto-
solic regions of CNR1 [5,18,31], we sought to determine
the effects of HINT1 on the cannabinoid-mediated nega-
tive control of glutamate NMDAR function. Our study in-
dicates that in the absence of receptor activation, different
GPCRs, including CNR1, collaborate with HINT1 proteins
to reduce the sensitivity of NMDARs to stimulation. How-
ever, upon GPCR activation, cannabinoids maintain
HINT1-mediated control over NMDAR activity and they
protect against NMDA-associated excitotoxicity.
Results
Increased NMDA-induced neuronal injury and the
absence of cannabinoid neuroprotection in HINT1−/−
cultured cortical neurons
The exposure of neuronal-enriched E16 murine cortical
cultures from wild-type (WT) (HINT1+/+) and HINT1−/−
mice to NMDA for 24 h resulted in a concentration-
dependent decrease in cell viability, as measured by LDH
release. In all cases, NMDA toxicity was greater in the
knockout cells (Figure 1A,E,F). Pre-treatment or co-
treatment with the cannabinoid agonist WIN55,212-2 re-
duced the toxicity of NMDA (30 μM) in the WT cultures
(Figure 1B,E,G). Furthermore, the effects of WIN55,212-2
against NMDA insult were abrogated upon treatment with
the CNR1 antagonist SR141716A (1 μM), which is consist-
ent with CNR1-mediated neuroprotection. However, in
the absence of HINT1, the positive effect of the cannabin-
oid agonist was absent (Figure 1B,F,H).
Figure 1 NMDA-induced neuronal injury in cortical cell cultures from WT and HINT1−/− mice. (A) Cultures were exposed to increasing
concentrations of NMDA for 24 h. Cell death was measured by LDH efflux into the medium. The data shown represent the mean ± S.E.M. from 20
wells per group. * Significant difference between WT and HINT1−/− cultured neurons, p < 0.05. (B) The cultures were exposed to a fixed concentration
of 30 μM NMDA for 24 h in the absence (−−) or presence of increasing concentrations of the cannabinoid agonist WIN55,212-2. To eliminate the
possible participation of cannabinoid receptor 2 (CNR2), the assay was conducted in the presence of 3 μM of the CNR2 antagonist JTE907.
Φ Significant difference compared to NMDA alone, p < 0.05. (C-H) Fluorescence photomicrograph of cortical cell cultures immunolabelled with an
anti-MAP2 antibody (Ab) (green) following treatment with vehicle (C and D), 30 μM NMDA (E and F) or 30 μM NMDA plus 100 nM WIN55,212-2
(G and H); the nuclei were counterstained with 4,6-diamidino-2-phenylindole. Inset: Immunodetection study of CNR1 (antibody C terminal sequence
461–472; Cayman Chemical, Mi, USA, 10006590) and HINT1 (antibody from Abnova H00003094-A01. Abyntek, Spain) in HINT1−/− cultured neurons
(40 μg/lane).
Vicente-Sánchez et al. Molecular Brain 2013, 6:42 Page 3 of 16
http://www.molecularbrain.com/content/6/1/42We then infected HINT1−/− cortical cultures with
lentiviral vectors expressing the HINT1 protein. Trans-
gene expression was significantly detected 3 days post-
transduction (Figure 2A). After NMDA exposure for
24 h (30 μM), the viability of the HINT1−/− neurons
transduced with pLVTHM-HINT1 (0.1 to 3 μL/well
lentiviral particles) was greater than the viability of
pLVTHM-transduced HINT1−/− neurons and WT
HINT1+/+ neurons (Figure 2B). Infection of HINT1−/−
neurons with 1 μL/well of the lentiviral particles also re-
stored WIN55,212-2-mediated neuroprotection against
NMDA toxicity (Figure 3A,B,C).The enhanced response of HINT1−/− neurons to
NMDAR activation
The function of NMDARs is linked to the activation of
nNOS and the NO-mediated regulation of zinc metabol-
ism (Figure 4) [5]. Certainly, the de-regulation of zinc
homeostasis has been shown to contribute to neurotoxicity
[45]. As the absence of HINT1 reduced cell viability in re-
sponse to NMDA insult, we explored the possibility that
NMDAR-mediated NO production and zinc release were
regulated by HINT1. We first determined whether the en-
dogenous content of zinc ions (both free ions plus those
complexed to proteins) was comparable in membranes
Figure 2 Lentiviral expression of HINT1 increases cell viability
in the presence of NMDA. (A) Fluorescence photomicrograph of
HINT1−/− cortical cell cultures uninfected or infected with lentiviral
particles. The cells were immunolabelled with anti-HINT1 Ab (green).
The nuclei were counterstained with 4,6-diamidino-2-phenylindole.
Inset: Immunodetection of HINT1. (B) The cultures were infected
and exposed to 30 μM of NMDA for 24 h. Cell death was measured
by LDH efflux into the medium. The data shown represent the
mean ± S.E.M. from 20 wells per experimental group. * Indicates a
significant difference between HINT1−/− cortical cell cultures, p < 0.05,
compared to those derived from WT mice. Φ Significant increase in cell
viability of HINT1−/− cortical cell cultures infected with increasing
amounts of the viral HINT1 vector compared to the HINT1−/− control
group, p < 0.05.
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HINT1−/− mice (Figure 4A). Then, we evaluated the
release of endogenous zinc in response to NMDAR activa-
tion. The incubation of mouse brain cortical slices with
NMDA increased Newport Green fluorescence, a measure
of zinc ion release from endogenous stores via nNOS/NO
in response to NMDAR activity. NMDAR-mediated zinc
release was attenuated by MK801 and prevented by NOS
inhibition (Figure 4B). However, NMDA evoked a signifi-
cantly greater mobilization of zinc ions in the absence of
HINT1. This enhancement was not observed for morphine
or WIN55,212-2, agonists of the MOR and CNR1,
suggesting that HINT1 regulates the activity of NMDARs
but not that of GPCRs (Figure 5).To further investigate the effects of HINT1 on NMDAR
function, whole-cell currents from CA1 pyramidal neu-
rons were recorded in hippocampal slices from HINT1+/+
and HINT1−/− mice. Whereas the activity of synaptic
NMDARs was only slightly increased in the preparations
from HINT1−/− mice, the amplitude of the spontaneous
slow inward currents that are selectively mediated by the
activation of extrasynaptic NMDA receptors was signifi-
cantly higher in HINT1−/− mice than in WT mice (mean
amplitudes: -100.7 ± 7.8 pA, n = 60 and −64 ± 5.7 pA, n =
40; in 10 and 8 neurons from HINT1 −/− and HINT1+/+
mice, respectively). The identity of these NMDAR cur-
rents was confirmed by their sensitivity to the NMDAR
antagonist D-AP5 [46-48]. To test whether these differ-
ences were specifically due to HINT1, we recorded the
NMDAR-mediated currents using purified protein in the
whole-cell recording pipette. The presence of HINT1 in
the intracellular solution did not affect the WT neurons
but reversed the changes observed in the transgenic mice
(mean amplitude: -70.6 ± 8.1 pA, n = 67, from 8 neurons)
(Figure 6A).
Compared to the HINT1+/+ controls, the HINT1−/−
mice demonstrated increased markers of NMDAR func-
tion, such as CaMKII pThr286 autophosphorylation [49]
and the phosphorylation of NR1 subunits on Ser897 [3],
which are both facilitated by PKA activity (Figure 6B).
Similarly, compared to the WT littermates, the HINT1−/−
mice displayed higher PKA activity and greater PKA-
induced CaMKII activation and NR1 C1 Ser897 phosphor-
ylation in response to stress induced by the forced
swimming test (Figure 6B). Thus, HINT1 negatively regu-
lates NMDAR function and is neuroprotective against
NMDA-induced excitotoxicity.
GPCRs diminish NMDAR responsiveness via HINT1
HINT1 is present in cortical cultures from mice deficient
in CNR1 (CNR1−/−), and these cells were more sensitive to
NMDA toxicity than cells from WT mice [42] (Figure 7).
As the HINT1 protein interacts with the cytosolic regions
of different GPCRs, including the CNR1, MOR, serotonin
5HT1A receptor and the dopamine D2 receptor [5-7,31],
we determined whether these GPCRs might assist HINT1
to negatively regulate NMDAR function. With the excep-
tion of the CNR1, most GPCRs are absent from neurons in
primary cultures that are established at this stage of onto-
genesis (from E16 embryos), including the dopamine D2
receptors, serotonin 5HT1/2 receptors and MORs [50-52],
and thus we forced their expression in these cells. Our re-
sults indicated that CNR1−/− cortical cultures transfected
with CNR1 receptors were much less sensitive to NMDA
insult (Figure 7A,B vs D,E), and the expression of GPCRs
in the CNR1−/− cultured neurons during this stage of
neural development also led to reduced NMDA toxicity.
Thus, 5HT1A receptors and MOR significantly reduced
Figure 3 The effect of lentiviral expression of HINT1 on WIN55,212-2-mediated neuroprotection against NMDA insult. The cell cultures
from WT and HINT1−/− mice were infected with 0.1 or 3 μL of lentiviral particles and exposed to NMDA for 24 h in the absence or presence of
100 nM of WIN55,212-2. Cell death was measured by LDH efflux into the medium. The data shown represent the mean ± S.E.M. from 20 wells per
condition. * Significant difference compared to NMDA alone, p < 0.05. Bottom: Fluorescence photomicrographs of NMDA-treated HINT1−/−
cortical cell cultures (A) uninfected or infected with HINT1 lentiviral particles either (B) without or (C) with WIN55,212-2. The cells were
immunolabelled with an anti-MAP2 Ab (green). The nuclei were counterstained with 4,6-diamidino-2-phenylindole.
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NMDAR activity (Figure 7), and this effect of the GPCRs
was not modified by their respective antagonists (NMDA
30 μM, antagonists 10 μM and % LDH release as mean ±
SEM), WAY100135 (5HT1AR) 42 ± 4, naltrexone (MOR)
48 ± 5, L-741,626 (D2R) 70 ± 6, SR141716A (CNR1) 42 ±
5, n=3). CNR1 agonists, such as WIN55,212-2, when used
in the nM range were protective against NMDA ex-
citotoxicity (Figure 1B). However, 1 μM concentrations of
the other GPCR agonists failed to provide protection
(DPAT (5HT1AR) 49 ± 4, morphine (MOR) 59 ± 5, or
quinpirole (D2R) 71 ± 6, n=3).
HINT1 facilitates the association between MOR/CNR1 and
NR1 subunits
MOR and CNR1 associate with NR1 subunits of
NMDARs [3,5], and the HINT1 protein stabilizes theirinteraction [5,53]. In synaptosomes from the adult mouse
cerebral cortex, both MOR and CNR1 co-precipitated
with the NR1 subunits, and this association was much
weaker in HINT1−/− mice (Figure 8A). In cortical cultures
from WT mice, the NR1 subunits co-precipitated with
CNR1 and HINT1. In HINT1−/− neurons, the amounts of
the NR1 subunits and CNR1 were similar to those in
HINT1+/+ neurons. However, in the absence of HINT1,
much less CNR1 co-precipitated with the NR1 subunits
compared to the WT cultures. Furthermore, infection of
HINT1−/− neurons with HINT1 lentiviral particles
increased HINT1 expression, which resulted in the co-
precipitation of CNR1 with the NR1 subunits (Figure 8B).
Our results further demonstrated that in WT HINT1+/+
cells, the presence of certain GPCRs was sufficient to
reduce the impact of NMDA insult and neuronal death
(Figure 7). This effect was related to the association of
Figure 4 NMDAR-mediated nNOS/NO activation and zinc release. A: SNAP release of endogenous zinc from cortical synaptosome
membranes obtained from wild-type and HINT1−/− mice. SNAP (100 μM) was added to cortical membranes and the assay was carried out at RT,
as described [30]. Left panel: Calibration curve for Zincon detection of Zn2+. Right panel: The NO donor was incubated with the membranes for
30 min and Zinc release was monitored by its complexing with the reporter (zinc chelator, Zincon). The absorbance at 600 nm was recorded at
RT on a BioChrom Ultrospec 2100 spectrophotometer (Cambridge, UK) and the data represent the mean ± SEM of three independent assays.
*Significantly different from the respective control group (without SNAP), p<0.05. SNAP produced comparable release of zinc ions from wild-type
and HINT1−/− synaptosome membranes. B: NMDAR-mediated production of NO and the subsequent release of zinc ions from endogenous
stores. The spontaneous endogenous zinc release was determined in Control (untreated) sections. The data shown were obtained at 30 min
post-treatment. The effect of NMDAR activation on zinc mobilization was then studied. Control: baseline vehicle; A stands for the agonist NMDA
used at 3 μM; MK801+A = 3 μM MK801 (NMDAR antagonist) + 3 μM NMDA; L-NNA+A = 10 μM L-NNA (NOS antagonist) + 3 μM NMDA. The
images were color indexed and presented in pseudocolor.
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via HINT1. Thus, we next investigated whether the dis-
sociation of NMDARs from MORs control would lead to
an increased responsiveness to their activators, which was
observed in cultured neurons in the absence of HINT1 or
CNR1. Opioids, such as morphine and DAMGO, promote
PKC-mediated dissociation of MOR from NR1 subunits
[3]. In these circumstances, intracerebroventricular (icv)
injection of NMDA to WT mice activated the NMDAR
effector CaMKII to a much greater extent than in micethat were not treated with these opioids and showed
MOR-NR1 association (Figure 8C).
Neuropathic pain is accompanied with an excess of
glutamate activity and the overactivation of NMDARs
[8]. Thus, we studied the stability of the MOR-NMDAR
complex in mice suffering from chronic constriction
injury (CCI), a model of neuropathic pain, for 7 days.
We found that the activity of the NMDAR/CaMKII
pathway was enhanced, and MOR was not associated
with the NR1 subunits (Figure 8C).
Figure 5 The absence of HINT1 increases NMDAR-mediated NO production and zinc mobilization in response to NMDA. Coronal mouse
frontal cortex slices from WT and HINT1−/− mice were preloaded with Newport Green diacetate, and fluorescent images were obtained using a
10 × 0.4 HC PL APO objective (excitation, 488; emission, 498–520). The cortical regions studied are indicated as A, B or C, and the data shown
were obtained 30 min post-treatment. NMDA was used at the concentrations indicated in the inset, and images for 1 μM and 3 μM are shown.
Morphine and WIN55,212-2 were used at 3 μM. The NMDAR antagonist MK801 was used at 3 μM, and the NOS inhibitor L-NNA was used at 10
μM. For each treatment, the assays for wild-type (WT) and HINT1−/− cortical slices were performed during the same run, and the images obtained
were color-indexed and presented in pseudocolor [31]. Scale bar = 500 μm. The assay was typically repeated 3 times, and the results were always
comparable. Representative images are shown. Inset: Linear regression and 95% confidence intervals of the zinc release promoted by increasing
concentrations of NMDA in cortical slices from WT and HINT1−/− mice.
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Our study showed that HINT1 inhibits the responsiveness
of glutamate NMDARs to exogenous and endogenous
activators when released during a mild stress response.This inhibition seems to be mediated by the interaction of
HINT1 proteins with NMDAR NR1 subunits and requires
the cooperation of non-activated GPCRs, such as CNR1,
MOR or 5-HT1AR. The absence of HINT1 weakened the
Figure 6 The effects of HINT1 on the responsiveness of NMDAR. (A) Spontaneous NMDAR-mediated currents in CA1 pyramidal neurons
from WT and HINT1−/− mice. The mean amplitudes of the spontaneous, NMDAR-mediated currents recorded in neurons from WT and HINT1−/−
mice in control conditions and when HINT1 was included in the solution of the recording pipette. The data are represented as the mean ± S.E.M.
from WT (n = 12) and HINT1−/− (n = 28) mice. * Significant difference p < 0.05. Representative whole-cell currents recorded from CA1 pyramidal
neurons from WT and HINT1−/− mice with the internal control solution and neurons recorded with HINT1 added to the internal solution. Higher
amplitudes of the NMDAR-mediated slow inward currents were observed in HINT1−/− mice relative to WT samples, which reverted in the
presence of HINT1. The NMDAR antagonist D-AP5 (50 μM) abolished these currents. (B) The effect of mild stress induced by the forced
swimming test on NMDAR activity in WT and HINT1−/− mice. Thr286 CaMKII autophosphorylation and PKA-mediated Ser897 NR1 phosphorylation
were measured in the controls and mice exposed to the test. Inset: PKA activity of cortical synaptosomes in WT and HINT1−/− mice.
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enhancing the responses of NMDARs to activators. The
activation of most GPCRs promotes that of NMDARs and
for the MOR, this is accompanied by the separation of
MOR-HINT1 complex from the NMDAR NR1 subunit.
Therefore, several GPCRs restrain the activity of NMDARs,
although this control can be released in response to their
activation, thereby contributing to NMDAR signaling. By
contrast, the activated CNR1 maintains a negative influence
on NMDAR gating, which facilitates its protective effect
against NMDA excitotoxicity. Thus, the HINT1 protein
emerges as an essential regulator of these GPCR-NMDAR
interactions.Synaptic NMDARs are mostly targeted to the postsyn-
aptic region of glutamatergic synapses, where they
structurally organize (and spatially restricted) into large
macromolecular signaling complexes composed of scaf-
folding and adaptor proteins. These structures physic-
ally link the NMDAR to kinases, phosphatases, GPCRs
and other signaling molecules [54,55]. Moreover, these
interactions between GPCRs and NMDARs may occur
more frequently than suspected, and physical interactions
between the dopamine D1 receptor, group I metabotropic
glutamate receptor (mGlu5a), MOR or CNR1 and the C1
segment of NMDAR NR1 subunits have also been
reported [3,5,56,57].
Figure 7 The expression of GPCRs reduces NMDAR activity. Cortical cell cultures from WT and CNR1−/− mice were exposed to NMDA for 24 h.
* Significant difference compared to WT cultured neurons, p < 0.05. Cell death induced by NMDA was also determined in cultures transfected with CNR1,
serotonin receptor type 1A (5HT1AR), Mu-opioid receptor (MOR) and dopaminergic receptor type 2 (D2R). Φ Significant difference in the CNR1−/− cultured
neurons that were not transfected with the corresponding GPCR, p < 0.05. The data shown represent the mean ± S.E.M. from 12 wells per experimental
group. Inset to CNR1 group: Fluorescence photomicrograph of CNR1−/− cortical cell cultures showing the expression of transfected CNR1 using Abs
against CNR1 (green) and MAP2 (red). The nuclei were counterstained with 4,6-diamidino-2-phenylindole. Bottom: The cells were immunolabelled with an
anti-MAP2 Ab (green) and assayed following treatment with vehicle (A and D), 30 μM of NMDA (B and E) or 30 μM of NMDA plus 100 nM of WIN55,212-2
(C and F). The expression of HINT1 in the CNR1−/− cortical cell cultures is shown.
Vicente-Sánchez et al. Molecular Brain 2013, 6:42 Page 9 of 16
http://www.molecularbrain.com/content/6/1/42In brain synaptosomes from HINT1−/− mice, the quan-
tities of the NR1 subunits, CNR1, MOR and zinc content
were similar to those in WT mice. However, in the absence
of HINT1 the association between these GPCRs and the
NR1 subunits weakened, and consequently, NMDARs
mobilized more zinc ions from endogenous stores than inthe WT controls. Thus, HINT1 stabilizes the coupling of
CNR1s with NMDAR NR1 subunits that is required for
cannabinoids to dampen NMDAR activity. Indeed, in
HINT1−/− cortical neurons NMDAR responsiveness is
enhanced and the presence of CNR1 was not sufficient
to inhibit this activity, with WIN55,212-2 failing to
Figure 8 MOR and CNR1 associate with the NR1 subunits via HINT1: Implications for NMDAR activity. (A) The association of GPCRs, MOR
and CNR1 with the NMDAR NR1 subunits is dependent on HINT1. The GPCRs were immunoprecipitated from solubilized mouse brain cortical
synaptosomes from WT and HINT1−/− mice, and the proteins that co-precipitated with the NR1 subunits were analyzed by western blot. (B) The
association of CNR1 with NR1 in WT and HINT1−/− cortical cell cultures uninfected or infected with 10 μL/well of HINT1−/− lentiviral particles. The
presence/absence of HINT1 was determined, and the co-precipitates of the NR1 subunits and CNR1 were then assessed by immunoprecipitation
and western blot. For each determination, cells from 10 wells were pooled, and the assay was repeated twice with identical results. (C) Opioid
agonists promoted a higher level of responsiveness of the NMDAR by inhibiting the association between MOR and NR1. Morphine or DAMGO
was icv-injected into the mice 24 h prior to the analysis of MOR/NMDA NR1 association and CaMKII activating autophosphorylation on Thr286.
At 7 days post-surgery, the mice from the CCI neuropathic pain group displayed increased pThr286 CaMKII and reduced MOR-NR1 association
compared to the sham-operated controls. Changes of Mechanical Withdrawal Threshold. Following ligation, animals developed significant
mechanical allodynia by day 3 that remained until day 21. Naïve control and sham – operated mice failed to exhibit mechanical allodynia. Data
are mean ± SEM. *P<0.05 vs. sham-operated group, ANOVA, followed by the Student-Newman-Keuls test (SigmaStat, SPSS Science Software,
Erkrath, Germany) p < 0.05.
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electrophysiological studies, hippocampal preparations
from HINT1−/− mice exhibit increased extrasynaptic
NMDAR current activity. Whereas synaptic NMDARs
contribute to neuroprotection, stimulation of extrasynaptic
NMDARs promotes cell death and a perturbation in this
balance is currently believed to contribute to the etiology of
neurodegenerative diseases [58]. Mood disorders, like
mania, concur with altered NMDAR function, and bipolar
disorder patients have fewer glial and neuronal cells [59,60].
Interestingly, when evaluated in the battery of conventional
behavioral tests, HINT1−/− mice displayed manic-like
behavior [61].
The activation of several GPCRs triggers that of the
associated NMDARs via PKC/Src, a signaling mechan-
ism that in certain situations negatively influences the
activity of the GPCR itself, as described for the MOR
[33]. The activity of the NMDAR within this regulatory
loop must be tightly controlled to prevent the conse-
quences of its de-regulation. By contrast, it is the activity
of the NMDARs themselves that makes the demands on
the endogenous cannabinoid system to control their cal-
cium currents [62]. Therefore, the association of CNR1s
with NR1 subunits through HINT1 proteins persists dur-
ing NMDAR activation, and cannabinoids then exert
negative control on the NMDARs’ activity [5]. The differ-
ences that GPCRs display in the regulation of NMDARs is
apparently unrelated to the class of G proteins they regu-
late, since while D1 regulates Gs/Gq [63], the MOR,
CNR1, D2R and 5HT1A regulate Gi/o, and Gq couples to
MOR, CNR1, 5HT2A [18,64-66]. It is possible that the as-
sociation of the HINT1 protein with the GPCR deter-
mines the relation of the latter with the NMDAR. Several
GPCRs bind the HINT1 protein through their cytosolic
regions, such as the MOR, CNR1, 5HT1AR, 5HT2AR,
muscarinic M2 and M4 receptors, α2 Adrenergic receptor,
dopamine D2 receptor [31], D1 receptor (unpublished ob-
servation), mostly through the C terminal or third internal
loop. Under physiological conditions, the resting CNR1
(as well as GPCRs like the MOR or the 5HT1A receptor)
interact with HINT1 proteins to downregulate the activity
of NMDARs, thereby restraining the overall NMDAR cur-
rents that could otherwise promote irreversible neuronal
damage. Thus, in the context of NMDAR regulation by
GPCRs, HINT1 emerges as an essential protein to protect
against neuronal damage.
We have characterized the dynamics of MOR-HINT1
and CNR1-HINT1 associations with NMDARs in terms
of receptor activation, identifying critical differences [5,6].
Opioids like morphine activate PKC, which disrupts the
association of MOR-HINT1 with NMDAR NR1 subunits.
However, when activated NMDARs recruit CaMKII
activity, this increases their association with CNR1s and
this is a relationship that is then further enhanced by PKC.These kinases remove certain proteins, probably RGS-Rz
proteins [6], from the CNR1-bound HINT1 protein,
thereby promoting its binding to NR1 subunits. CaMKII
plays different roles in CNR1 and MOR regulation, and
whereas this kinase activity is implicated in MOR
desensitization [67], in the CNR1-HINT1 environment it
prevents the action of PKC on the NR1 C1 segment that
would separate both receptors. Those GPCRs that
enhance NMDAR function through the activation of PKC,
intracellular Ca2+ release and Src activation, also promote
serine phosphorylation of NR1 C1 [1,4,68], comparable to
that which occurs with the MOR. For other receptors that
couple to and inhibit NMDARs, it would be necessary to
address the molecular mechanisms behind their effects
and to compare them with those of CNR1s.
The complex GPCR-HINT1 can interact with the C1
segment of NMDAR NR1 subunits [5] and this inter-
action reduces the gating of the tretrameric ionotropic
receptor. The regulation of calcium fluxes permeating the
NMDAR is complex and results from an interplay be-
tween different systems. Glutamate, glycine and D-serine
bind to the extracellular domains of the NR1 and NR2/3
subunits, which augments calcium transit. Zinc ions
co-released with glutamate reach micromolar concentra-
tions in the cleft and they diminish the responsiveness of
NMDARs to activation [69], these zinc ions displaying a
higher affinity for NR2A subunits than NR2B subunits
[70]. The sensitivity of the NMDAR to extracellular stim-
uli is regulated by the serine, threonine and tyrosine phos-
phorylation/dephosphorylation of cytosolic residues on
the NR1/2 subunits [2,71]. By contrasts, PKC phosphory-
lates the NR1 subunits, which blocks the binding of nega-
tive regulators [72,73], and Src acts on the NR2A/B
subunits to remove the tonic inhibition of extracellular
zinc [74], resulting in an increase in the entry of extracel-
lular calcium. The protein phosphatase calcineurin re-
verses the phosphorylation of the regulatory C1 region of
the NR1 subunits and it plays an important role in the in-
activation of NMDARs [75], probably favoring the binding
of negative regulators. Moreover, the striatal-enriched
protein tyrosine phosphatase (STEP) reverses the Src-
mediated upregulation of NMDAR activity [76].
The control of NMDAR function is also achieved by dir-
ect physical interactions with third party proteins like
calmodulin (CaM) and probably GPCR-HINT1. The
calcium-dependent inactivation (CDI) of NMDARs is a
negative feedback response that downregulates the gating
of NMDAR channels and the calcium-binding protein
CaM plays a key role in this response. The cytoskeletal
protein α-actinin2 interacts with the C0 region of the NR1
subunits and calcium-activated CaM promotes CDI by
releasing the NMDAR complex from the cytoskeleton.
The NR1 C1 segment binds Ca2+-CaM rather than CaM,
and this binding reduces the “open” probability of the
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PKC phosphorylates the C1 region at Ser890 and Ser896,
and it blocks Ca2+-CaM binding [80,81], thereby promot-
ing NMDAR activity. Thus, when coupled to non-
activated GPCRs HINT1 binds to this C1 region of the
NR1 subunits and like Ca2+-CaM it inhibits NMDAR
function [5] present study. In this context, the activation
of GPCRs like the MOR and mGlu1α enhances NMDAR
activity in a PKC-dependent manner, which releases GPCR-
HINT1 inhibition and prevents the binding of Ca2+-CaM
by acting on serines in the NR1 C1 domain, and both
these effects increase the “open” probability of the
calcium channel [3,4,80].
In the CCI animal model of neuropathic pain in which
NMDARs are more sensitive to glutamatergic activation,
these receptors were separated from the MOR and then
released from the control of HINT1. An interesting obser-
vation is that cerebral ischemia induces the accumulation
of dopamine, serotonin and other neurotransmitters that
contribute to neuronal death [82]. Accordingly, MOR
antagonists, dopaminergic or serotonergic nerve depletors
and glutamate antagonists prevent or reduce the brain
injury that results from experimental heatstroke [83,84].
While antagonists targeting MOR or 5HT2AR protect
against heatstroke, agonists of CNR1, the delta opioid
receptor (DOR), 5HT1AR or mGluR7 also appear to be
beneficial [85-87]. These observations suggest that in the
absence of agonists, GPCRs can diminish NMDAR
calcium fluxes via HINT1. However, in function of the
GPCR, its activation can either enhance NMDAR respon-
siveness or maintain the inhibition of NMDAR function.
CNR1 is highly efficacious in counteracting the neuronal
damage resulting from NMDAR overactivation, although
other GPCRs like DOR, 5HT1AR and mGluR7, could also
potentially provide neuroprotection.Conclusions
The GPCRs CNR1 and MOR negatively regulate NMDAR
responsiveness by interacting with the HINT1 protein.
While the control of NMDAR function can be achieved
without GPCR activation, many of these agonists were
shown to disrupt the GPCR-HINT1 association with NR1
subunits and increase NMDAR responsiveness to activa-
tion. Notwithstanding, CNR1 cannabinoids counteracted
the negative effects of NMDAR-mediated excitotoxicity
and preserved cell viability. As several GPCRs show func-
tional cross-talk with ion channels these interactions
might support therapeutic and also undesirable effects of
available drugs [88]. Thus, elucidating the role of HINT1
in GPCR regulation of glutamate NMDAR activity will im-
prove our understanding of the mechanisms behind
NMDAR-mediated neuronal damage and may provide
novel therapeutic targets.Methods
Animal studies
A mouse knock-out strain, 96% genetic background from
129 mice, with targeted disruption of HINT1 (a gift from
I.B. Weinstein/J.B. Wang) and wild-type littermate mice
were used for this study. Genotyping was performed on
the basis of the protocol described previously [6]. All the
procedures for handling and sacrificing animals followed
the European Commission guidelines (Council Directive
86/609/EEC) and approved by the Committee on Animal
Care at CSIC. NMDA was administered in vivo as de-
scribed previously [3].
Forced swim test: The test was based on the original
version of the forced swim test of Porsolt for mice [89].
Mice were placed in a 5 L cylinder (40 cm high, 25 cm
diameter) filled with 3.5 L of water, where they swam
without the possibility to touch the bottom. Mice were
placed in water through a series of four trials of 6 min
each and immobility was recorded during the last 4 min
of each trial using a stopwatch. Immobility was deter-
mined when the mouse was only making movements
necessary to keep its head above the water and
maintained a stationary posture; a stopwatch was started
within the first 2 sec immobility was observed.
Chronic constriction injury (CCI): After testing mice for
their basal mechanical sensitivity, CCI was performed
under isoflurane/oxygen anesthesia using a modification
of the Bennett and Xie procedure [90]. Briefly, the sciatic
nerve was exposed at the mid-thigh level, proximal to its
trifurcation, and two 5/0 braided silk suture ligatures
(Lorca Marin, Murcia, Spain, 70014) were tied loosely
around the sciatic nerve, 1–2 mm apart. Sham CCI
surgery was carried out identically, except that no ligations
were placed around the nerve.Primary cortical cell culture
Neuron-enriched mouse cerebral cortical cultures were
prepared from the brains of embryonic day-16 wild-type
129 and HINT1 knockout mice. Cerebral cortices were
dissociated and seeded (1.25 × 105 cells/cm2) onto
multiwell dishes coated with poly-D-lysine. After 3 hours,
the culture medium was changed to Neurobasal medium
supplemented with B-27, GlutaMAX and antibiotics (100
IU/mL Penicillin and 100 μg/mL Streptomycin solution)
(Invitrogen, Paisley, UK). From days 5 to 7 in vitro, cyto-
sine arabinoside (5 μM) was added to the cultures to
eliminate the majority of proliferating non-neuronal cells.
Cultures were maintained at 37°C in a humidified 5% CO2
incubator. In some cases, cells were evaluated after trans-
fection for 72 h, with the concentrated lentiviral vector
coding the HINT1 protein cDNA. In a set of experiments,
cultures from CNR1 receptor knockout mice, generously
donated by Dr. A. Araque [91], were used.
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Between days 12 and 14 in vitro, cultures were rinsed
with serum-free minimal essential medium and treated
for 24 h with NMDA, with or without other drugs. Cell
death was quantified by measuring lactate dehydrogen-
ase (LDH, Roche) release into the bathing medium over
24 h and was expressed as a percentage of cell death
induced by a maximally cytotoxic concentration (500
μM) of NMDA: (LDH - LDHcontrol)/(LDHNMDA -
LDHcontrol) × 100%.
Immunocytochemistry
Cells plated onto poly-D-lysine coated 10 mm-glass
coverslips were fixed in 4% paraformaldehyde for 10
min, incubated in 10% normal goat serum (NGS) and
0.1% Triton X-100 in phosphate buffer saline (PBS).
The cells were immunolabeled with MAP2ab (M1406,
Sigma-Aldrich, Madrid, Spain) and for CNR1 receptor
(10006590, Cayman Chemical, Ann Arbor, Michigan)
for 2h at room temperature. The cells were then incu-
bated with Alexa fluor 488 or 594 conjugated secondary
antibodies (Invitrogen) and finally with 4,6-diamidino-
2-phenylindole (DAPI), before mounting in Mowiol
solution (Calbiochem, San Diego, CA). Slides were
observed with a Leica DMI 6000 inverted fluorescence
microscope (Leica Microsistemas S.L.U., Barcelona,
Spain). Controls were performed to confirm the specifi-
city of the primary and secondary antibodies.
Lentiviral vector production
RNAs isolated from mouse brain lysates were reverse-
transcribed using the SuperScript® III First-Strand Synthesis
System (Invitrogen) following the manufacturer’s instruc-
tions. The cDNAs for the murine HINT1 (NM_008248)
was then amplified by PCR and subsequently cloned in the
pLVTHM “Tet on” inducible vector downstream of the H1
promoter. Cloned inserts were sequenced to verify the
integrity of each construct.
Lentiviruses were prepared by cotransfecting 10 μg
pLVTHM vector (carrying either HINT1 cDNAs or the
empty plasmid), 6.5 μg second generation packaging
plasmid (psPAX2) and 3.5 μg envelope plasmid (pMD2.G)
into HEK-293T cells. Transfections were carried out with
a 1:3 volumetric mix of DNA and FuGENE® 6 Transfec-
tion Reagent (Roche). Lentivirus-containing supernatants
were collected 48 and 72 h after transfection, filtered
through 0.22-μm-pore nitrocellulose, concentrated by
ultracentrifugation, aliquoted, and stored at − 80°C until
used. The titer of lentivirus was determined by hole-by-di-
lution titer assay.
Hippocampal slice preparation and electrophysiology
Cortical hippocampal slices were obtained from wild-
type 129 and HINT1 knockout mice (13–15 days old).Animals were decapitated and brains were rapidly
removed and placed in ice-cold artificial cerebrospinal
fluid containing (in mM): 124 NaCl, 2.7 KCl, 1.25
KH2PO4, 2 MgSO4, 26 NaHCO3, 10 glucose, 0.4 ascorbic
acid and 2 CaCl2, and gassed with 95% O2/5% CO2 (pH
7.3). Slices were incubated for >45 minutes at room
temperature and then transferred to an immersion re-
cording chamber and superfused with Mg2+-free ice-cold
artificial cerebrospinal fluid (ACSF) containing (in mM): 124
NaCl, 2.7 KCl, 1.25 KH2PO4, 26 NaHCO3, 10 glucose, 4
CaCl2, 0.01 glycine, 0.05 picrotoxin (to block GABA A
receptors) and gassed with 95% O2/5% CO2 (pH 7.3).
Extracellular Mg2+ was omitted to maximize NMDAR-
mediated currents. Cells were visualized under an Olympus
BX50WI microscope equipped with infrared and differential
interference contrast imaging devices, and with a 40x water-
immersion objective.
Electrophysiological recordings from CA1 pyramidal neu-
rons were made using the whole-cell patch-clamp tech-
nique with an internal solution containing (in mM): 135
KGluconate, 10 KCl, 10 HEPES, 1 MgCl2 and 2 ATP-Na2
(pH 7.4). Neurons were recorded in voltage-clamp condi-
tions with the membrane potential held at – 70 mV.
NMDA receptor-mediated currents were isolated in the
presence of 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX;
to block AMPA-kainate receptors; 20 μM). When indi-
cated, the purified r-HINT1 protein was included in the in-
ternal solution at a final concentration of 150 nM. Signals
were fed to a Pentium-based PC through a DigiData 1440A
interface board. Signals were filtered at 1 KHz and acquired
at 10 KHz sampling rate. The pCLAMP 10.2 (Axon instru-
ments, Sunnyvale, CA) software was used for data acquisi-
tion and storage.Immunoprecipitation and Western blotting
Preparation of membrane from cortical cell cultures and
immunoprecipitation of NR1 subunits was performed as
described previously [3]. The immunocomplexes were
recovered and proteins were resolved by SDS/polyacryl-
amide gel electrophoresis (PAGE). The separated proteins
were then transferred onto 0.2 μm polyvinylidene
difluoride (PVDF) membranes (BioRad 162–0176), probed
with the primary antibodies to HINT1 (Abnova
H00003094-A01. Abyntek, Spain) and CNR1 (C terminal
sequence 461–472; Cayman Chemical, Mi, USA,
10006590), and detected using secondary antibodies conju-
gated to horseradish peroxidase. Antibody binding was
visualized by chemiluminescence and recorded with a
ChemiImager IS-5500 (Alpha Innotech, San Leandro,
California). Densitometry was performed using Quantity
One Software (BioRad) and expressed as the mean ± SEM
of the integrated volume (average optical density of the
pixels within the object area/mm2).
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The Pep Tag protein kinase A assay (Promega, Madison,
WI, USA) was used for assessing total PKA enzymatic ac-
tivity according to the manufacturer’s instructions. Briefly,
brain lysates were prepared using RIPA buffer at 4°C. The
homogenate was then centrifuged at 18,000×g for 15 min
at 4°C. The supernatants were incubated for 2 min at 30°C
and for 30 min at 30°C with the specific substrate in the
presence of activating solution. The reaction was stopped
at 95°C for 10 min. The PKA-induced phosphorylation
specifically changes the net charge of the fluorescent pep-
tide substrate from +1 to −1. Consequently peptides were
separated according to their net charges via electrophor-
esis in 0.8% agarose in 50 mM Tris–HCl (pH 8.0) in a
horizontal gel at 100 V for 15 min. The phosphorylated
peptide migrated towards the anode and the non-
phosphorylated peptide to the cathode.
Zinc-microfluorescence imaging in mouse cortical slices
Coronal mouse frontal cortex slices (200 μm; 2.50-1.50
mm to bregma) from WT and HINT1−/− mice were oxy-
genated and preloaded with 50 μM of the cell-permeable
Newport Green diacetate (50 μM; N7991, Invitrogen),
0.1% pluronic acid and 0.5% dimethyl sulfoxide for 1h as
described elsewhere [30]. The permeated probe remains
trapped and that remaining in the extracellular millieu
was removed before adding the substances under study
and performing Intracellular Zn2+ imaging. The effects
of the following compounds were assayed: NMDA; the
NMDAR antagonist MK801; the NOS/NO inhibitor
LNNA (Tocris, UK, 0664). Images were obtained by
confocal microscopy through a 10 × 0.4 HC PL APO
objective on a Leica DMIII 6000 CS confocal fluores-
cence microscope equipped with a TCS SP5 scanning
laser (excitation, 488 nm; emission, 498–520 nm). The
size and resolution of the captured images were identical
and before data analysis it was verified that within the
area under study variations in pixel luminosity were
normally distributed (Systat Software, Inc., Erkrath,
Germany). For each concentration of NMDA and animal
group (WT and HINT1−/−) differences of luminosity
means between control and NMDA-treated images were
computed (AlphaEase FC Software, San Leandro, CA,
USA). The data were analyzed to determine correlation
coefficients and 95% of confidence intervals of WT and
HINT1−/− groups and plotted (Sigmaplot/Sigmastat v12,
Erkrath, Germany). The images were color indexed and
presented in pseudocolor [31].
Spectrophotometric detection of zinc released from
cortical synaptosomes
Samples (0.5 mL total volume) were prepared by adding
100 μL of cortical membrane suspension, vehicle or the
NO donor (S)-Nitroso-N-acetylpenicillamine (SNAP) to400 μL of Hepes buffer (25 mM; pH 7.8; treated with
Chelex-100 resin (BioRad). The zinc ion releasing effect of
SNAP on brain synaptosomes reached a maximum when
used at 100 μM for 30 min [30]. Calibration samples were
prepared from ZnCl2 (100 mM) solution (Sigma 39059)
and Hepes buffer. For blanks, the metal solution was
substituted with Chelex-100-treated water. Complexation
was initiated by the addition of the zinc chelator Zincon
(Sigma #96440) (stock solution 1.6 mM in NaOH 1 M) to
reach a final concentration of 40 μM. Absorption spectra
(600 nm) were recorded after 20 min of sample incubation
at room temperature (RT) on a BioChrom Ultrospec 2100
spectrophotometer (Cambridge, UK).
Drugs and primary antibodies
R(+)-Win 55212 was purchased from Sigma-Aldrich
(Madrid, Spain), N-Methyl-d-aspartate (NMDA), Ly320135,
JTE907, MK801, LNNA, DAMGO and AP5 were obtained
from Tocris (Abingdon, UK). Morphine sulfate was from
Merck (Darmstadt, Germany). Recombinant HINT1 protein
was obtained as previously described [3,6]. The antibodies
used in this study were: MAP2ab (M1406, Sigma-Aldrich,
Madrid, Spain), HINT1 (Abnova H00003094-A01, Abyntek,
Spain) and CNR1 receptor (10006590, Cayman Chemical,
Ann Arbor, Michigan) NMDAR1 (Abcam ab1880); Ca2+/cal-
modulin-dependent protein kinase II (BD 611292);
Phospho- Ca2+/calmodulin-dependent protein kinase II
(CaMKII Thr286, Cell Signaling 3361).
Data analysis
Data were expressed as mean ± S.E.M. ANOVA, followed
by the Student-Newman-Keuls test (SigmaStat, SPSS
Science Software, Erkrath, Germany) was performed and
significance was defined as P < 0.05.
Abbreviations
CCI: Chronic constriction injury; CNR1: Cannabinoid receptor type 1; GPCRs: G
protein-coupled receptors; HINT1: Histidine triad nucleotide-binding protein
1; LDH: Lactate dehydrogenase; MOR: Mu-opioid receptor; NMDA: N-methyl-
D-aspartate; PAGE: SDS/polyacrylamide gel electrophoresis; PKC: Protein
kinase C; PKCi: Protein kinase C-interacting protein..
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AVS, PSB and MRM performed the experiments. JG and PSB conceived and
designed the study and wrote the paper. All authors read and approved the
final manuscript.
Acknowledgements
We would like to thank Gabriela de Alba, Concha Bailón and Marta Gomez
for their excellent technical assistance. Funding: This research was supported
by “Plan Nacional de Drogas 2011–014 (JG) & MINECO, SAF-2012/34991 (JG)
and FIS PI11/01704 (PS-B)”.
Received: 22 August 2013 Accepted: 19 September 2013
Published: 5 October 2013
Vicente-Sánchez et al. Molecular Brain 2013, 6:42 Page 15 of 16
http://www.molecularbrain.com/content/6/1/42References
1. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, et al: G-protein-
coupled receptors act via protein kinase C and Src to regulate NMDA
receptors. Nat Neurosci 1999, 2:331–338.
2. Salter MW, Kalia LV: Src kinases: a hub for NMDA receptor regulation.
Nat Rev Neurosci 2004, 5:317–328.
3. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Berrocoso E,
Garzón J: The Mu-Opioid receptor and the NMDA receptor associate in
PAG neurons: implications in pain control. Neuropsychopharmacology
2012, 37:338–349.
4. Chen L, Huang LY: Sustained potentiation of NMDA receptor-mediated
glutamate responses through activation of protein kinase C by a m
opioid. Neuron 1991, 7:319–326.
5. Sánchez-Blázquez P, Rodríguez-Muñoz M, Vicente-Sánchez A, Garzón J:
Cannabinoid receptors couple to NMDA receptors to reduce the
production of NO and the mobilization of zinc induced by glutamate.
Antioxid Redox Signal 2013. 10.1089/ars.2012.5100.
6. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Bailón C,
Martín-Aznar B, Garzón J: The histidine triad nucleotide-binding protein 1
supports mu-opioid receptor-glutamate NMDA receptor cross-regulation.
Cell Mol Life Sci 2011, 68:2933–2949.
7. Guang W, Wang H, Su T, Weinstein IB, Wang JB: Role of mPKCI, a novel
mu-opioid receptor interactive protein, in receptor desensitization,
phosphorylation, and morphine-induced analgesia. Mol Pharmacol 2004,
66:1285–1292.
8. Liu XJ, Salter MW: Glutamate receptor phosphorylation and trafficking in
pain plasticity in spinal cord dorsal horn. Eur J Neurosci 2010, 32:278–289.
9. Liu Q, Bhat M, Bowen WD, Cheng J: Signaling pathways from cannabinoid
receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated
calcium influx and neurotoxicity in dorsal root ganglion neurons.
J Pharmacol Exp Ther 2009, 331:1062–1070.
10. Zhuang SY, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE, et al:
Cannabinoids produce neuroprotection by reducing intracellular calcium
release from ryanodine-sensitive stores. Neuropharmacology 2005,
48:1086–1096.
11. Li Q, Yan H, Wilson WA, Swartzwelder HS: Modulation of NMDA and
AMPA-mediated synaptic transmission by CB1 receptors in frontal
cortical pyramidal cells. Brain Res 2010, 1342:127–137.
12. Hohmann AG, Briley EM, Herkenham M: Pre- and postsynaptic distribution
of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res
1999, 822:17–25.
13. Ong WY, Mackie K: A light and electron microscopic study of the CB1
cannabinoid receptor in the primate spinal cord. J Neurocytol 1999,
28:39–45.
14. Salio C, Fischer J, Franzoni MF, Conrath M: Pre- and postsynaptic
localizations of the CB1 cannabinoid receptor in the dorsal horn of the
rat spinal cord. Neuroscience 2002, 110:755–764.
15. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, et al:
Involvement of cannabinoid receptors in the regulation of neurotransmitter
release in the rodent striatum: a combined immunochemical and
pharmacological analysis. J Neurosci 2005, 25:2874–2884.
16. Rodriguez JJ, Mackie K, Pickel VM: Ultrastructural localization of the CB1
cannabinoid receptor in mu-opioid receptor patches of the rat Caudate
putamen nucleus. J Neurosci 2001, 21:823–833.
17. Marchalant Y, Cerbai F, Brothers HM, Wenk GL: Cannabinoid receptor
stimulation is anti-inflammatory and improves memory in old rats.
Neurobiol Aging 2008, 29:1894–1901.
18. Garzón J, de la Torre-Madrid E, Rodríguez-Muñoz M, Vicente-Sánchez A,
Sánchez-Blázquez P: Gz mediates the long-lasting desensitization of brain
CB1 receptors and is essential for cross-tolerance with morphine.
Mol Pain 2009, 5:11.
19. Fan N, Yang H, Zhang J, Chen C: Reduced expression of glutamate
receptors and phosphorylation of CREB are responsible for in vivo
Delta9-THC exposure-impaired hippocampal synaptic plasticity.
J Neurochem 2010, 112:691–702.
20. Brenner C: Hint, Fhit, and GalT: function, structure, evolution, and
mechanism of three branches of the histidine triad superfamily of
nucleotide hydrolases and transferases. Biochemistry 2002, 41:9003–9014.
21. Lima CD, Klein MG, Weinstein IB, Hendrickson WA: Three-dimensional
structure of human protein kinase C interacting protein 1, a member of
the HIT family of proteins. Proc Natl Acad Sci U S A 1996, 93:5357–5362.22. McDonald JR, Groschel-Stewart U, Walsh MP: Properties and distribution of the
protein inhibitor (Mr 17,000) of protein kinase C. Biochem J 1987, 242:695–705.
23. Huebner K, Saldivar JC, Sun J, Shibata H, Druck T: Hits, Fhits and Nits:
beyond enzymatic function. Adv Enzyme Regul 2011, 51:208–217.
24. Weiske J, Huber O: The histidine triad protein Hint1 triggers apoptosis
independent of its enzymatic activity. J Biol Chem 2006, 281:27356–27366.
25. Li H, Zhang Y, Su T, Santella RM, Weinstein IB: Hint1 is a haplo-insufficient
tumor suppressor in mice. Oncogene 2006, 25:713–721.
26. Huber O, Weiske J: Beta-catenin takes a HIT. Cell Cycle 2008, 7:1326–1331.
27. Linde CI, Feng B, Wang JB, Golovina VA: Histidine triad nucleotide-binding
protein 1 (HINT1) regulates Ca(2+) signaling in mouse fibroblasts and
neuronal cells via store-operated Ca(2+) entry pathway. Am J Physiol Cell
Physiol 2013, 304:C1098–C1104.
28. Ajit SK, Ramineni S, Edris W, Hunt RA, Hum WT, Hepler JR, et al: RGSZ1
interacts with protein kinase C interacting protein PKCI-1 and modulates
mu opioid receptor signaling. Cell Signal 2007, 19:723–730.
29. Rodríguez-Muñoz M, Torre-Madrid E, Sánchez-Blázquez P, Wang JB, Garzón
J: NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17
complex bound to the C terminus of mu-opioid receptors. Cell Signal
2008, 20:1855–1864.
30. Rodríguez-Muñoz M, Torre-Madrid E, Sánchez-Blázquez P, Garzón J: NO-
released zinc supports the simultaneous binding of Raf-1 and
PKCgamma cysteine-rich domains to HINT1 protein at the mu-opioid
receptor. Antioxid Redox Signal 2011, 14:2413–2425.
31. Sánchez-Blázquez P, Rodríguez-Muñoz M, Bailón C, Garzón J: GPCRs
promote the release of zinc ions mediated by nNOS/NO and the Redox
transducer RGSZ2 protein. Antioxid Redox Signal 2012, 17:1163–1177.
32. Garzón J, Rodríguez-Muñoz M, Sánchez-Blazquez P: Direct association of
mu-opioid and NMDA glutamate receptors supports their cross-
regulation: molecular implications for opioid tolerance. Curr Drug Abuse
Rev 2012, 5:199–226.
33. Rodríguez-Muñoz M, Garzón J: Nitric oxide and zinc-mediated protein
assemblies involved in mu opioid receptor signaling. Mol Neurobiol 2013.
10.1007/s12035-013-8465-z.
34. Inoue M, Mishina M, Ueda H: Locus-specific rescue of GluRe1 NMDA
receptors in mutant mice identifies the brain regions important for
morphine tolerance and dependence. J Neurosci 2003, 23:6529–6536.
35. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by
the NMDA receptor antagonist MK-801. Science 1991, 251:85–87.
36. Lipton SA: Paradigm shift in neuroprotection by NMDA receptor
blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160–170.
37. Mechri A, Saoud M: Khiari G, d’Amato T, Dalery J, Gaha L: Glutaminergic
hypothesis of schizophrenia: clinical research studies with ketamine.
Encéphale 2001, 27:53–59.
38. Maeng S: Zarate Jr CA: The role of glutamate in mood disorders: results
from the ketamine in major depression study and the presumed cellular
mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007,
9:467–474.
39. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, et al:
Ketamine produces effective and long-term pain relief in patients with
Complex Regional Pain Syndrome Type 1. Pain 2009, 145:304–311.
40. Chapman V, Haley JE, Dickenson AH: Electrophysiologic analysis of
preemptive effects of spinal opioids on N-methyl-D-aspartate receptor-
mediated events. Anesthesiology 1994, 81:1429–1435.
41. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz
B: Involvement of brain-derived neurotrophic factor in cannabinoid
receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004,
19:1691–1698.
42. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA: Molecular mechanisms of
cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol
2006, 69:691–696.
43. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al:
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990,
87:1932–1936.
44. Twitchell W, Brown S, Mackie K: Cannabinoids inhibit N- and P/Q-type calcium
channels in cultured rat hippocampal neurons. J Neurophysiol 1997, 78:43–50.
45. Sensi SL, Jeng JM: Rethinking the excitotoxic ionic milieu: the emerging
role of Zn(2+) in ischemic neuronal injury. Curr Mol Med 2004, 4:87–111.
46. Angulo MC, Kozlov AS, Charpak S, Audinat E: Glutamate released from glial
cells synchronizes neuronal activity in the hippocampus. J Neurosci 2004,
24:6920–6927.
Vicente-Sánchez et al. Molecular Brain 2013, 6:42 Page 16 of 16
http://www.molecularbrain.com/content/6/1/4247. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G: Neuronal
synchrony mediated by astrocytic glutamate through activation of
extrasynaptic NMDA receptors. Neuron 2004, 43:729–743.
48. Perea G, Araque A: Properties of synaptically evoked astrocyte calcium
signal reveal synaptic information processing by astrocytes. J Neurosci
2005, 25:2192–2203.
49. Makhinson M, Chotiner JK, Watson JB, O’Dell TJ: Adenylyl cyclase
activation modulates activity-dependent changes in synaptic strength
and Ca2+/calmodulin-dependent kinase II autophosphorylation.
J Neurosci 1999, 19:2500–2510.
50. Valdenaire O, Maus-Moatti M, Vincent JD, Mallet J, Vernier P: Retinoic acid
regulates the developmental expression of dopamine D2 receptor in rat
striatal primary cultures. J Neurochem 1998, 71:929–936.
51. Roth BL, Hamblin MW, Ciaranello RD: Developmental regulation of 5-HT2 and
5-HT1c mRNA and receptor levels. Brain Res Dev Brain Res 1991, 58:51–58.
52. Maloteaux JM, Octave JN, Laterre EC, Laduron PM: Down-regulation of 3H-
lofentanil binding to opiate receptors in different cultured neuronal
cells. Naunyn Schmiedebergs Arch Pharmacol 1989, 339:192–199.
53. Sánchez-Blázquez P, Rodríguez-Muñoz M, Berrocoso E, Garzón J: The
plasticity of the association between mu-opioid receptor and glutamate
ionotropic receptor N in opioid analgesic tolerance and neuropathic
pain. Eur J Pharmacol 2013. 10.1016/j.ejphar.2013.01.066.
54. Kim E, Sheng M: PDZ domain proteins of synapses. Nat Rev Neurosci 2004,
5:771–781.
55. Sans N, Wang PY, Du Q, Petralia RS, Wang YX, Nakka S, et al: mPins
modulates PSD-95 and SAP102 trafficking and influences NMDA
receptor surface expression. Nat Cell Biol 2005, 7:1179–1190.
56. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F: Regulation of dopamine D1
receptor function by physical interaction with the NMDA receptors.
J Neurosci 2004, 24:1149–1158.
57. Perroy J, Raynaud F, Homburger V, Rousset MC, Telley L, Bockaert J, et al:
Direct interaction enables cross-talk between ionotropic and group I
metabotropic glutamate receptors. J Biol Chem 2008, 283:6799–6805.
58. Hardingham GE, Bading H: Synaptic versus extrasynaptic NMDA receptor
signalling: implications for neurodegenerative disorders. Nat Rev Neurosci
2010, 11:682–696.
59. Rajkowska G: Cell pathology in mood disorders. Semin Clin Neuropsychiatry
2002, 7:281–292.
60. Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S, et al:
Peripheral profiling analysis for bipolar disorder reveals markers associated
with reduced cell survival. Proteomics 2011, 11:94–105.
61. Jackson KJ, Wang JB, Barbier E, Chen X, Damaj MI: Acute behavioral effects
of nicotine in male and female HINT1 knockout mice. Genes Brain Behav
2012. 10.1111/j.1601-183X.2012.00827.x.
62. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al:
CB1 cannabinoid receptors and on-demand defense against excitotoxicity.
Science 2003, 302:84–88.
63. Jin LQ, Wang HY, Friedman E: Stimulated D(1) dopamine receptors couple
to multiple Galpha proteins in different brain regions. J Neurochem 2001,
78:981–990.
64. Johnson-Farley NN, Kertesy SB, Dubyak GR, Cowen DS: Enhanced activation
of Akt and extracellular-regulated kinase pathways by simultaneous
occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A
receptors in PC12 cells. J Neurochem 2005, 92:72–82.
65. Sánchez-Blázquez P, Gómez-Serranillos P, Garzón J: Agonists determine the
pattern of G-protein activation in mu-opioid receptor-mediated
supraspinal analgesia. Brain Res Bull 2001, 54:229–235.
66. Wang HY, Undie AS, Friedman E: Evidence for the coupling of Gq protein
to D1-like dopamine sites in rat striatum: possible role in dopamine-
mediated inositol phosphate formation. Mol Pharmacol 1995, 48:988–994.
67. Garzón J, Rodríguez-Díaz M, López-Fando A, García-España A, Sánchez-
Blázquez P: Glycosylated phosducin-like protein long regulates opioid
receptor function in mouse brain. Neuropharmacology 2002, 42:813–828.
68. Guo W, Zou S, Guan Y, Ikeda T, Tal M, Dubner R, et al: Tyrosine
phosphorylation of the NR2B subunit of the NMDA receptor in the
spinal cord during the development and maintenance of inflammatory
hyperalgesia. J Neurosci 2002, 22:6208–6217.
69. Peters S, Koh J, Choi DW: Zinc selectively blocks the action of N-methyl-D-
aspartate on cortical neurons. Science 1987, 236:589–593.
70. Williams K: Separating dual effects of zinc at recombinant N-methyl-D-
aspartate receptors. Neurosci Lett 1996, 215:9–12.71. Lieberman DN, Mody I: Regulation of NMDA channel function by
endogenous Ca(2+)-dependent phosphatase. Nature 1994, 369:235–239.
72. Chakravarthy B, Morley P, Whitfield J: Ca2+−calmodulin and protein kinase
Cs: a hypothetical synthesis of their conflicting convergences on shared
substrate domains. Trends Neurosci 1999, 22:12–16.
73. Lau LF, Huganir RL: Differential tyrosine phosphorylation of N-methyl-D-
aspartate receptor subunits. J Biol Chem 1995, 270:20036–20041.
74. Zheng F, Gingrich MB, Traynelis SF, Conn PJ: Tyrosine kinase potentiates
NMDA receptor currents by reducing tonic zinc inhibition. Nat Neurosci
1998, 1:185–191.
75. Choe ES, Shin EH, Wang JQ: Inhibition of protein phosphatase 2B
upregulates serine phosphorylation of N-methyl-D-aspartate receptor
NR1 subunits in striatal neurons in vivo. Neurosci Lett 2005, 384:38–43.
76. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P,
et al: Therapeutic implications for striatal-enriched protein tyrosine
phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev 2012,
64:65–87.
77. Zhang S, Ehlers MD, Bernhardt JP, Su CT, Huganir RL: Calmodulin mediates
calcium-dependent inactivation of N-methyl-D-aspartate receptors.
Neuron 1998, 21:443–453.
78. Krupp JJ, Vissel B, Thomas CG, Heinemann SF, Westbrook GL: Interactions
of calmodulin and alpha-actinin with the NR1 subunit modulate
Ca2+−dependent inactivation of NMDA receptors. J Neurosci 1999,
19:1165–1178.
79. Merrill MA, Malik Z, Akyol Z, Bartos JA, Leonard AS, Hudmon A, et al:
Displacement of alpha-actinin from the NMDA receptor NR1 C0 domain
by Ca2+/calmodulin promotes CaMKII binding. Biochemistry 2007,
46:8485–8497.
80. Hisatsune C, Umemori H, Inoue T, Michikawa T, Kohda K, Mikoshiba K, et al:
Phosphorylation-dependent regulation of N-methyl-D-aspartate
receptors by calmodulin. J Biol Chem 1997, 272:20805–20810.
81. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, et al:
Characterization of protein kinase A and protein kinase C
phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit
using phosphorylation site-specific antibodies. J Biol Chem 1997,
272:5157–5166.
82. Lin MT: Heatstroke-induced cerebral ischemia and neuronal damage.
Involvement of cytokines and monoamines. Ann N Y Acad Sci 1997,
813:572–580.
83. Chang CK, Chang CP, Chiu WT, Lin MT: Prevention and repair of
circulatory shock and cerebral ischemia/injury by various agents in
experimental heatstroke. Curr Med Chem 2006, 13:3145–3154.
84. Chen ZC, Kuo JR, Huang YP, Lin MT: Mu-opioid receptor blockade protects
against circulatory shock and cerebral ischemia during heatstroke.
J Cardiovasc Pharmacol 2005, 46:754–760.
85. Chang CP, Chen SH, Lin MT: Ipsapirone and ketanserin protects against
circulatory shock, intracranial hypertension, and cerebral ischemia
during heatstroke. Shock 2005, 24:336–340.
86. Gu Z, Liu W, Wei J, Yan Z: Regulation of N-methyl-D-aspartic acid (NMDA)
receptors by metabotropic glutamate receptor 7. J Biol Chem 2012,
287:10265–10275.
87. He X, Sandhu HK, Yang Y, Hua F, Belser N, Kim DH, et al: Neuroprotection
against hypoxia/ischemia: delta-opioid receptor-mediated cellular/
molecular events. Cell Mol Life Sci 2012.
88. Dingledine R, Borges K, Bowie D, Traynelis SF: The glutamate receptor ion
channels. Pharmacol Rev 1999, 51:7–61.
89. Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary
screening test for antidepressants. Arch Int Pharmacodyn Ther 1977,
229:327–336.
90. Bennett GJ, Xie YK: A peripheral mononeuropathy in rat that produces
disorders of pain sensation like those seen in man. Pain 1988, 33:87–107.
91. Navarrete M, Araque A: Endocannabinoids mediate neuron-astrocyte
communication. Neuron 2008, 57:883–893.
doi:10.1186/1756-6606-6-42
Cite this article as: Vicente-Sánchez et al.: HINT1 protein cooperates with
cannabinoid 1 receptor to negatively regulate glutamate NMDA
receptor activity. Molecular Brain 2013 6:42.
